Last $4.11 USD
Change Today +0.08 / 1.99%
Volume 772.9K
XOMA On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 12:22 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

xoma corp (XOMA) Snapshot

Open
$4.07
Previous Close
$4.03
Day High
$4.21
Day Low
$4.03
52 Week High
03/4/14 - $9.57
52 Week Low
05/8/14 - $3.42
Market Cap
439.4M
Average Volume 10 Days
1.2M
EPS TTM
$-1.14
Shares Outstanding
106.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for XOMA CORP (XOMA)

xoma corp (XOMA) Related Bloomberg News

View More Bloomberg News

xoma corp (XOMA) Related Businessweek News

No Related Businessweek News Found

xoma corp (XOMA) Details

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. Its proprietary products comprise gevokizumab, a humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III studies for non-infectious uveitis, Behçet’s uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, cardiovascular disease, Schnitzler syndrome, and other diseases, as well as diseases under the neutrophilic dermatoses designation; and various proof-of-concept studies, including polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis. The company’s proprietary products also include XOMA metabolic activating, sensitizing, and antagonizing/deactivating antibodies that are in preclinical stage for the treatment of diabetes patients; XOMA 3AB, a multi-antibody product for the treatment of human botulism poisoning; and XOMA 629, a topical anti-bacterial product for the treatment of human immune system. In addition, it develops ACEON, an angiotensin converting enzyme inhibitor product; FDC1, a perindopril arginine and amlodipine besylate product; and HCD122 and LFA102 programs for the treatment of cancer. Further, the company licenses Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX antibody discovery, optimization, and development technologies. It has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Pfizer Inc.; and Margaux Biologics, Inc. The company was founded in 1981 and is headquartered in Berkeley, California.

172 Employees
Last Reported Date: 05/7/14
Founded in 1981

xoma corp (XOMA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $489.3K
Founder, Chief Scientific Officer, Executive ...
Total Annual Compensation: $417.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $347.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $391.4K
Chief Commercial Officer and Vice President
Total Annual Compensation: $380.0K
Compensation as of Fiscal Year 2013.

xoma corp (XOMA) Key Developments

XOMA Corporation - Special Call

To discuss the communication plan for its EYEGUARD(TM)-B clinical program

XOMA Corporation Approves Amendment to its Certificate of Incorporation

XOMA Corporation at its annual meeting of stockholders held on May 22, 2014, approved amendment to the company's certificate of incorporation to increase the number of authorized shares of its common stock, par value $0.0075 per share, by an additional 138,666,666 to 277,333,332 shares.

XOMA Corporation Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 02:00 PM

XOMA Corporation Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 02:00 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: John W. Varian, Chief Executive Officer, President and Director, Paul D. Rubin, Chief Medical Officer and Senior Vice President of Research & Development.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XOMA:US $4.11 USD +0.08

XOMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
arGEN-X BV €8.47 EUR +0.11
BioInvent International AB kr2.84 SEK -0.04
Dyax Corp $9.19 USD +0.3913
Genmab A/S kr210.50 DKK +1.50
Intrexon Corp $23.04 USD +0.77
View Industry Companies
 

Industry Analysis

XOMA

Industry Average

Valuation XOMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.5x
Price/Book 247.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XOMA CORP, please visit www.xoma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.